{"id":"b3f4e92b049c","type":"article","url":"https://hartvaat.nl/2021/09/21/pcsk9-remming-en-geoxideerde-fosfolipiden/","title":"PCSK9-remming en geoxideerde fosfolipiden","title_en":"PCSK9 Inhibition and Oxidized Phospholipids.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["enlicitide","niet-statine-therapie","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.07.031","source_url":"https://doi.org/10.1016/j.jacc.2021.07.031","authors":["Harpreet S Bhatia","Calvin Yeang","Amos Baruch","Xiaohong Yang","Erik S G Stroes","Sotirios Tsimikas"],"significance":6,"published":"2021-09-21","source_date":"2021-09-21","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/residueel-cardiovasculair-risico/"],"congress":"","summary_en":"This study examined the effect of PCSK9 inhibition on oxidized phospholipids, exploring whether evolocumab reduces these atherogenic mediators as an additional mechanism of cardiovascular protection beyond LDL lowering.","created":"2026-07-03T10:29:23Z","updated":"2026-07-03T13:28:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Studie naar het effect van PCSK9-remming op geoxideerde fosfolipiden als marker voor residueel cardiovasculair risico.","abstract_original":""}